[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Soterix Medical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100615071","phase-2-parcel-guided-rtms-for-major-depressive-disorder-100615071",false,"NCT07287839","Parcel-guided rTMS for Major Depressive Disorder","Phase-2 Trial of Parcel-guided rTMS for Major Depressive Disorder","Inclusion Criteria:\n\n* DSM-5 diagnosis of major depressive disorder confirmed using the Mini International Neuropsychiatric Interview (MINI30) Axis 1 and mood modules\n* Treatment-resistant MDD during the current major depressive episode documented in the MGH Antidepressant Treatment History Questionnaire (ATRQ31), which will be defined as being non-responders (less than 50% of symptom improvement) to two or more depression treatment trials of adequate dose and duration as defined by the MGH ATRQ.\n* At least moderate depression severity, operationalized as Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 20\n\nExclusion Criteria:\n\n* Ever met criteria for a psychotic disorder (Sz, SzAff, Bipolar disorder)\n* Anorexia nervosa or bulimia nervosa within the last year\n* Unstable medical condition by history, physical exam or laboratory results\n* Currently pregnant or breastfeeding women; fecund women not using adequate contraceptive methods or with plan to become pregnant\n* Contraindications to MRI (based on metal screening form)\n* Meets criteria for claustrophobia\n* Recent drug or alcohol use disorder with DSM-5 specifier of moderate or severe within 6 months, or mild within 2 months; or lifetime history of IV drug use A- ctively suicidal, as defined by expressive ideation with a plan or with suicidal ideation that requires immediate medical or treatment intervention.\n* Neurological or neuromuscular disorder\n* Requires medications for a general medical condition that contraindicate the TMS treatment\n* Prior non-response to ECT, vagal nerve stimulation (VNS) or deep brain stimulation (DBS)\n* History of ketamine treatment within 6 months\n* History of monoamine oxidase inhibitor (MAOI) within the past month\n* Lacks capacity to consent\n* Taking medications that increase the risk of seizures.\n* For patients on permitted concomitant psychotropic agents (antidepressants, anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, omega-3 fatty acids, folate, l-methylfolate, s-adenosyl methionine, lithium) dosing must be stable for at least four weeks prior to study entry and patients must agree to continue at the same dose during the study","ALL","18 Years","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study comparing standard repetitive transcranial magnetic stimulation (rTMS) for Depression to a novel targeting approach using brain surface parcellation to locate a specific brain target.",[27],"Treatment Resistant Depression (TRD)",[29,30,31,32],"rTMS","TMS","parcel-guided","beam-F3","NOT_YET_RECRUITING","2025-12-17",{"date":36,"type":37},"2025-12-18","ACTUAL",{"date":39,"type":21},"2025-12-15",{"date":41,"type":21},"2028-06-15",{"name":43,"class":44},"Soterix Medical","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100616604","phase-1-ketamine-biomarker-validation-100616604","NCT07307768","Ketamine Biomarker Validation","EEG Biomarker Development for Ketamine Administration","Inclusion Criteria:\n\n* Physically healthy patients who meet DMS-5 criteria for a major depressive episode (MDE) in the context of MDD and who score at least 22 on the Montgomery-Åsberg Depression Rating Scale (MADRS)\n* If taking antidepressants, dose is stable for at least 6 weeks.\n\nExclusion Criteria:\n\n* Lifetime history of bipolar disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder, including MDD with psychotic features\n* A first-degree relative with bipolar disorder, schizoaffective disorder, or schizophrenia, with the potential participant younger than 33 years (i.e., still at age of risk for a psychotic disorder)\n* Receipt of electroconvulsive therapy within 3 months of enrolling in the study\n* History of IV drug use\n* Nonresponse or intolerance to ketamine administered either clinically or as part of a prior research study\n* Pregnancy, planning to conceive, or sexually active but not using adequate birth control.\n* Actively suicidal (CSSRS≥3)\n* No antipsychotics or medications (e.g. benzodiazepines, anti-epileptics) that are likely to interact with GABA or glutamate,","59 Years",{"count":54,"type":21},20,[56],"PHASE1","We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.",[27],[60,61,62,63,64,65],"Ketamine","EEG","Depression","MDD","unipolar Depression","Biomarker",{"date":67,"type":37},"2025-12-29",{"date":69,"type":21},"2025-12-20",{"date":71,"type":21},"2028-03-01",{"name":43,"class":44},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":73},"100596189","transcranial-direct-current-stimulation-for-depression-100596189","NCT07042217","Transcranial Direct Current Stimulation for Depression","A Randomized, Double-blind, Parallel-arm, Sham-controlled Trial of ElectraRx Mindfulness Transcranial Direct Current Treatment System (Elect-MDS) for Adults With Major Depressive Disorder","Inclusion Criteria:\n\n* Clinically stable patients that meet criteria for diagnosis of MDD according to DSM-V-TR and confirmed with the Mini International Neuropsychiatric interview\n* Currently experiencing a major depressive episode of at least 4 week's duration as part of a unipolar depression\n* QIDS-SR score \\>11 on all three days of screening week (Days 1,3, 7)\n* Scored at least 17 (inclusive) on the HDRS-17 at trial entry\n* Any antidepressant medication is stable ≥ 30 days prior to HDRS-17 screening\n* Female patients are allowed if not pregnant and using a medically acceptable method of contraception, if of childbearing potential.\n\nExclusion Criteria:\n\n* Failure to respond to at least 2 antidepressant medications\n* Drug or alcohol abuse or dependence in the preceding 3 months\n* Concurrent benzodiazepine medication\n* High suicide risk assessed during clinician screening at baseline interview.\n* Failure to respond to ECT treatment or rTMS treatment in this or any previous episode.\n* Current DSM-V-TR psychotic disorder\n* History of clinically defined neurological disorder or insult that may impact participation in this study as determined by study physician\n* Metal in the cranium or skull defects\n* Implanted pump, neurostimulator, cardiac pacemaker or defibrillator\n* Skin lesions on scalp at the proposed electrode sites\n* Pregnancy","22 Years",{"count":83,"type":21},25,[85],"NA","This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.",[88],"Unipolar Depression",[90,91,92,93,94],"tDCS","mindulness","tES","electrotherapy","depression","RECRUITING","2025-11-06",{"date":98,"type":37},"2025-11-10",{"date":100,"type":37},"2025-07-01",{"date":102,"type":21},"2026-09-01",{"name":43,"class":44},""]